China 3D cardiac mapping Market by Application (Electroanatomical Mapping, Basket Catheter Mapping, and Real-Time Positional Management EP System) and End User (Hospitals, Clinics, and Diagnostics Centers): Opportunity Analysis and Industry Forecast, 2020-2027
The China 3D cardiac mapping market was valued at $55.55 million in 2019 and is projected to reach $150.59 million by 2027, registering a CAGR of 12.8% from 2020 to 2027.
Cardiac mapping is the process of identifying electrical or mechanical activity of human heart. Mapping electrical movements of heart is a critical component for diagnosis and treatment of any heart disease. Cardiac mapping is generally performed by inserting a catheter into the heart chamber percutaneously and sequentially recording endocardial electrograms within a precise location within the heart. 3D cardiac mapping systems give three-dimensional view of a patient’s heart, which helps electrophysiologists to identify the site of origin of any irregular rhythm accurately and deliver radio-frequency catheter ablation therapy with high success rate. Moreover, cardiac mapping is used widely for identification, characterization, and localization of arrhythmia.
Surge in prevalence of cardiac arrhythmias and increased demand for improved patient outcomes mainly boosts the market growth. Cardiac arrhythmias have increased the incidences of other risk factors such as CVDs, high blood pressure, obesity, and diabetes. The chances of developing cardiac arrhythmias increases with increase in age. The common type of cardiac arrhythmias is atrial fibrillation, which causes an irregular and fast heart beat; there are numerous factors responsible for irregular heart rhythm such as heart attack, smoking, congenital heart defects, and stress. Improving life expectancies of people has considerably increased the geriatric population across the globe. These aspects have increased the demand for early detection and treatment of irregular heartbeat, thereby driving the demand for 3D cardiac mapping systems.
The China 3D cardiac mapping market is segmented on the basis of application and end user. By application, it is divided into electroanatomical mapping, basket catheter mapping, and real-time positional management (cardiac pathways) EP system. By end user, it is segmented into hospitals, clinics and diagnostics centers
Some of the key players operating in the market include Abbott Laboratories, Microport Scientific Corporation, Medtronic Plc, and Acutus Medical.
KEY MARKET SEGMENTS
By Application
Cardiac mapping is the process of identifying electrical or mechanical activity of human heart. Mapping electrical movements of heart is a critical component for diagnosis and treatment of any heart disease. Cardiac mapping is generally performed by inserting a catheter into the heart chamber percutaneously and sequentially recording endocardial electrograms within a precise location within the heart. 3D cardiac mapping systems give three-dimensional view of a patient’s heart, which helps electrophysiologists to identify the site of origin of any irregular rhythm accurately and deliver radio-frequency catheter ablation therapy with high success rate. Moreover, cardiac mapping is used widely for identification, characterization, and localization of arrhythmia.
Surge in prevalence of cardiac arrhythmias and increased demand for improved patient outcomes mainly boosts the market growth. Cardiac arrhythmias have increased the incidences of other risk factors such as CVDs, high blood pressure, obesity, and diabetes. The chances of developing cardiac arrhythmias increases with increase in age. The common type of cardiac arrhythmias is atrial fibrillation, which causes an irregular and fast heart beat; there are numerous factors responsible for irregular heart rhythm such as heart attack, smoking, congenital heart defects, and stress. Improving life expectancies of people has considerably increased the geriatric population across the globe. These aspects have increased the demand for early detection and treatment of irregular heartbeat, thereby driving the demand for 3D cardiac mapping systems.
The China 3D cardiac mapping market is segmented on the basis of application and end user. By application, it is divided into electroanatomical mapping, basket catheter mapping, and real-time positional management (cardiac pathways) EP system. By end user, it is segmented into hospitals, clinics and diagnostics centers
Some of the key players operating in the market include Abbott Laboratories, Microport Scientific Corporation, Medtronic Plc, and Acutus Medical.
KEY MARKET SEGMENTS
By Application
- Electroanatomical Mapping
- Basket Catheter Mapping
- Real-Time Positional Management (Cardiac Pathways) EP System.
- Hospitals
- Clinics
- Diagnostics
- Abbott Laboratories
- Microport Scientific Corporation
- Medtronic Plc
- Acutus Medical
CHAPTER 1: INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1.CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five forces analysis
3.4.Market dynamics
3.4.1.Drivers
3.4.1.1.Surge in prevalence of cardiac arrhythmias
3.4.1.2.Rise in geriatric population.
3.4.1.3.Growth in preference for minimally invasive procedures
3.4.2.Restraint
3.4.2.1.High Cost of 3D Cardiac Mapping Systems
3.4.3.Opportunity
3.4.3.1.Rise in Preference for 3D Cardiac Mapping
3.4.3.2.Rise in the Healthcare Expenditure in China
3.5.Impact of government regulations on China 3d cardiac mapping market
CHAPTER 4: CHINA 3D CARDIAC MAPPING MARKET, BY TECHNOLOGY
4.1.Overview
4.1.1.Market size and forecast
4.2.Electroanatomical mapping
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.3.Basket catheter mapping
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.4.Real-time positional management (cardiac pathways) EP system
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
CHAPTER 5: CHINA 3D CARDIAC MAPPING MARKET, BY END USER
5.1.Overview
5.1.1.Market size and forecast
5.2.Hospitals
5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast
5.3.Clinics
5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast
5.4.Diagnostics centers
5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Market size and forecast
CHAPTER 6: COMPANY PROFILES
6.1.Abbott Laboratories
6.1.1.Company overview
6.1.2.Company snapshot
6.1.3.Operating business segments
6.1.4.Product portfolio
6.1.5.Business performance
6.1.6.Key strategic moves and developments
6.2.Acutus Medical
6.2.1.Company overview
6.2.2.Company snapshot
6.2.3.Operating business segments
6.2.4.Product portfolio
6.2.5.Key strategic moves and developments
6.3.MicroPort Scientific Corporation
6.3.1.Company overview
6.3.2.Company snapshot
6.3.3.Operating business segments
6.3.4.Product portfolio
6.3.5.Business performance.
6.4.Medtronic Plc.
6.4.1.Company overview
6.4.2.Company snapshot
6.4.3.Operating business segments
6.4.4.Product portfolio
6.4.5.Business performance
6.4.6.Key strategic moves and developments
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1.CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five forces analysis
3.4.Market dynamics
3.4.1.Drivers
3.4.1.1.Surge in prevalence of cardiac arrhythmias
3.4.1.2.Rise in geriatric population.
3.4.1.3.Growth in preference for minimally invasive procedures
3.4.2.Restraint
3.4.2.1.High Cost of 3D Cardiac Mapping Systems
3.4.3.Opportunity
3.4.3.1.Rise in Preference for 3D Cardiac Mapping
3.4.3.2.Rise in the Healthcare Expenditure in China
3.5.Impact of government regulations on China 3d cardiac mapping market
CHAPTER 4: CHINA 3D CARDIAC MAPPING MARKET, BY TECHNOLOGY
4.1.Overview
4.1.1.Market size and forecast
4.2.Electroanatomical mapping
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.3.Basket catheter mapping
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.4.Real-time positional management (cardiac pathways) EP system
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
CHAPTER 5: CHINA 3D CARDIAC MAPPING MARKET, BY END USER
5.1.Overview
5.1.1.Market size and forecast
5.2.Hospitals
5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast
5.3.Clinics
5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast
5.4.Diagnostics centers
5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Market size and forecast
CHAPTER 6: COMPANY PROFILES
6.1.Abbott Laboratories
6.1.1.Company overview
6.1.2.Company snapshot
6.1.3.Operating business segments
6.1.4.Product portfolio
6.1.5.Business performance
6.1.6.Key strategic moves and developments
6.2.Acutus Medical
6.2.1.Company overview
6.2.2.Company snapshot
6.2.3.Operating business segments
6.2.4.Product portfolio
6.2.5.Key strategic moves and developments
6.3.MicroPort Scientific Corporation
6.3.1.Company overview
6.3.2.Company snapshot
6.3.3.Operating business segments
6.3.4.Product portfolio
6.3.5.Business performance.
6.4.Medtronic Plc.
6.4.1.Company overview
6.4.2.Company snapshot
6.4.3.Operating business segments
6.4.4.Product portfolio
6.4.5.Business performance
6.4.6.Key strategic moves and developments
LIST OF TABLES
TABLE 01.CHINA 3D CARDIAC MAPPING MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 02.CHINA 3D CARDIAC MAPPING MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 03.ABBOTT: COMPANY SNAPSHOT
TABLE 04.ABBOTT: OERATING SEGMENT
TABLE 05.ABBOTT: PRODUCT PORTFOLIO
TABLE 06.ABBOTT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 07.ACUTUS: COMPANY SNAPSHOT
TABLE 08.ACUTUS: OPERATING SEGMENTS
TABLE 09.ACUTUS: PRODUCT PORTFOLIO
TABLE 10.ACUTUS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 11.MICROPORT: COMPANY SNAPSHOT
TABLE 12.MICROPORT: OPERATING SEGMENTS
TABLE 13.MICROPORT: PRODUCT PORTFOLIO
TABLE 14.MEDTRONIC: COMPANY SNAPSHOT
TABLE 15.MEDTRONIC: OPERATING BUSINESS SEGMENTS
TABLE 16.MEDTRONIC: PRODUCT PORTFOLIO
TABLE 17.MEDTRONIC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 01.CHINA 3D CARDIAC MAPPING MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 02.CHINA 3D CARDIAC MAPPING MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 03.ABBOTT: COMPANY SNAPSHOT
TABLE 04.ABBOTT: OERATING SEGMENT
TABLE 05.ABBOTT: PRODUCT PORTFOLIO
TABLE 06.ABBOTT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 07.ACUTUS: COMPANY SNAPSHOT
TABLE 08.ACUTUS: OPERATING SEGMENTS
TABLE 09.ACUTUS: PRODUCT PORTFOLIO
TABLE 10.ACUTUS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 11.MICROPORT: COMPANY SNAPSHOT
TABLE 12.MICROPORT: OPERATING SEGMENTS
TABLE 13.MICROPORT: PRODUCT PORTFOLIO
TABLE 14.MEDTRONIC: COMPANY SNAPSHOT
TABLE 15.MEDTRONIC: OPERATING BUSINESS SEGMENTS
TABLE 16.MEDTRONIC: PRODUCT PORTFOLIO
TABLE 17.MEDTRONIC: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 01.SEGMENTATION OF CHINA 3D CARDIAC MAPPING MARKET
FIGURE 02.TOP INVESTMENT POCKETS IN SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2017–2020*
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENTS, 2017–2020* (%)
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2017–2020*
FIGURE 06.MODERATE: BARGAINING POWER OF BUYERS
FIGURE 07.MODERATE: BARGAINING POWER OF SUPPLIERS
FIGURE 08.LOW: THREAT OF NEW ENTRANTS
FIGURE 09.LOW: THREAT OF SUBSTITUTION
FIGURE 10.MODERATE COMPETITIVE RIVALRY
FIGURE 11.CHINA 3D CARDIAC MAPPING MARKET: RESTRAINTS, AND DRIVERS
FIGURE 12.CHINA 3D CARDIAC MAPPING MARKET FOR ELECTROANATOMICAL MAPPING, 2019 & 2027($ MILLION)
FIGURE 13.CHINA 3D CARDIAC MAPPING MARKET FOR BASKET CATHETER MAPPING, 2019 & 2027($ MILLION)
FIGURE 14.CHINA 3D CARDIAC MAPPING MARKET FOR REAL-TIME POSITIONAL MANAGEMENT (CARDIAC PATHWAYS) EP SYSTEM, 2019 & 2027($ MILLION)
FIGURE 15.CHINA 3D CARDIAC MAPPING MARKET, FOR HOSPITALS, 2019 & 2027 ($MILLION)
FIGURE 16.CHINA 3D CARDIAC MAPPING MARKET, FOR CLINICS, 2019 & 2027 ($MILLION)
FIGURE 17.CHINA 3D CARDIAC MAPPING MARKET, FOR DIAGNOSTIC CENTER, 2019 & 2027 ($MILLION)
FIGURE 18.ABBOTT: NET SALES, 2017–2019 ($MILLION)
FIGURE 19.ABBOTT: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 20.ABBOTT: REVENUE SHARE, BY REGION, 2019(%)
FIGURE 21.MICROPORT: NET SALES, 2017–2019 ($MILLION)
FIGURE 22.MICROPORT: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 23.MICROPORT: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 24.MEDTRONIC: NET SALES, 2017–2019 ($MILLION)
FIGURE 25.MEDTRONIC: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 26.MEDTRONIC: REVENUE SHARE BY REGION, 2019 (%)
COMPANIES MENTIONED
Abbott Laboratories, Microport Scientific Corporation, Medtronic Plc, and Acutus Medical
FIGURE 01.SEGMENTATION OF CHINA 3D CARDIAC MAPPING MARKET
FIGURE 02.TOP INVESTMENT POCKETS IN SMART INSULIN OR GLUCOSE RESPONSIVE INSULIN MARKET
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2017–2020*
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENTS, 2017–2020* (%)
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2017–2020*
FIGURE 06.MODERATE: BARGAINING POWER OF BUYERS
FIGURE 07.MODERATE: BARGAINING POWER OF SUPPLIERS
FIGURE 08.LOW: THREAT OF NEW ENTRANTS
FIGURE 09.LOW: THREAT OF SUBSTITUTION
FIGURE 10.MODERATE COMPETITIVE RIVALRY
FIGURE 11.CHINA 3D CARDIAC MAPPING MARKET: RESTRAINTS, AND DRIVERS
FIGURE 12.CHINA 3D CARDIAC MAPPING MARKET FOR ELECTROANATOMICAL MAPPING, 2019 & 2027($ MILLION)
FIGURE 13.CHINA 3D CARDIAC MAPPING MARKET FOR BASKET CATHETER MAPPING, 2019 & 2027($ MILLION)
FIGURE 14.CHINA 3D CARDIAC MAPPING MARKET FOR REAL-TIME POSITIONAL MANAGEMENT (CARDIAC PATHWAYS) EP SYSTEM, 2019 & 2027($ MILLION)
FIGURE 15.CHINA 3D CARDIAC MAPPING MARKET, FOR HOSPITALS, 2019 & 2027 ($MILLION)
FIGURE 16.CHINA 3D CARDIAC MAPPING MARKET, FOR CLINICS, 2019 & 2027 ($MILLION)
FIGURE 17.CHINA 3D CARDIAC MAPPING MARKET, FOR DIAGNOSTIC CENTER, 2019 & 2027 ($MILLION)
FIGURE 18.ABBOTT: NET SALES, 2017–2019 ($MILLION)
FIGURE 19.ABBOTT: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 20.ABBOTT: REVENUE SHARE, BY REGION, 2019(%)
FIGURE 21.MICROPORT: NET SALES, 2017–2019 ($MILLION)
FIGURE 22.MICROPORT: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 23.MICROPORT: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 24.MEDTRONIC: NET SALES, 2017–2019 ($MILLION)
FIGURE 25.MEDTRONIC: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 26.MEDTRONIC: REVENUE SHARE BY REGION, 2019 (%)
COMPANIES MENTIONED
Abbott Laboratories, Microport Scientific Corporation, Medtronic Plc, and Acutus Medical
